REDUCED VOLUME CAPACITOR FOR IN VIVO DEFIBRILLATOR

用于体内除颤器的小容量电容器

• 批准号: 2229717
• 负责人: ANTON C GREENWALD
• 金额: $ 7.5万
• 依托单位: SPIRE CORPORATION
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-05-01 至 1994-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2229717
• 关键词: barium; biomedical equipment development; ceramics; dielectric property; implant; implantable defibrillators; molecular film; strontium; titanium; vapor

Over one-third the volume of in-the-body heart defibrillators is devoted to the capacitor, which consumes approximately 20 cm3; this volume could be reduced to less than 1 cm3 using proven integrated circuit technology. Employing metalorganic chemical vapor deposition (MOCVD), Spire proposes to form thin film ceramic capacitors having at least a hundred times greater energy density than is presently available from commercial products. MOCVD makes this possible by eliminating the voids and other field enhancing defects which limit capacitor performance. Spire's capacitors will be barium-strontium-titanate-based and will feature extremely high dielectric constant (over 1,000) and breakdown strength (100 V/micromoles). In Phase I, a single-layer 1 mu F, 1000 V capacitor will be fabricated and demonstrated as proof-of-principle that full-sized prototype capacitors can be built in Phase Il, where they would be made available to manufacturers of defibrillators for testing. Successful completion of the proposed program will lead to immediate introduction of smaller devices with improved patient comfort.

超过三分之一的体积是体内除颤器的体积 给电容器，该电容器消耗约20 cm3；这个卷可以 使用经过验证的集成电路技术将其降低到小于1 cm3。 Spire使用金属有机化学蒸气沉积（MOCVD）提出 形成至少一百次的薄膜陶瓷电容器 比目前可以使用的能量密度更高 产品。 MOCVD通过消除空隙和其他 限制电容器性能的现场增强缺陷。尖顶的 电容器将是基于钡丁烷的钡，将具有 极高的介电常数（超过1,000）和故障强度 （100 v/sricromoles）。 在第一阶段，将制造一个单层1 Mu F，1000 V电容器，并且 显示全尺寸原型电容器的原理证明 可以在IL期间建造，可以在其中提供 用于测试的除颤器的制造商。成功完成 拟议的计划将立即引入较小的设备 随着患者的舒适度改善。